The U.S. Food and Drug Administration issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics relevant to the regulation of GenAI-enabled medical devices.

This study analyses the EU digital health market and economic impact of digital health technologies, including AI-enabled solutions.

This area is a priority workstream for the AI Office, reflecting its importance for AI innovation and competitiveness. The study Observatory for digital health technologies in Europe was commissioned by the Directorate-General for Communications Networks, Content and Technology (DG CONNECT).

Aston University and BioCare Ltd are working together to create a unique AI-powered digital health tool that can deliver personalised nutritional and lifestyle advice by analysing data from health tests and questionnaires.

Along with ongoing support, the app will empower its users to make long-term and lasting improvements to their health and wellbeing.

The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate information on emerging infectious diseases affecting humans, animals, and the environment.

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal perspective in order to enhance AI capabilities and EU regulatory frameworks.

Commencing in February 2025, the FORSEE (Forging Successful AI Applications for European Economy and Society) project is funded through the Beyond the horizon: A human-friendly deployment of artificial intelligence and related technologies funding call under the Horizon Europe programme.

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment comes from the European Innovation Council (EIC) Fund, which is part of the EU research and innovation programme Horizon Europe.

University of Houston researchers and their students are developing a new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases.

CellChorus Inc., a spinoff from the University of Houston, is commercializing the UH-developed Time-lapse Imaging Microscopy In Nanowell Grids™ platform for dynamic single-cell analysis with label-free analysis. Now they've received a $2.5 million grant from the National Center for Advancing Translational Sciences of the National Institutes of Health to fast-track the development of an advanced "label-free" version of this technology in partnership with the University of Houston.